Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced the first patient dosing in an open, multi-center Phase II study. The study is designed to assess the safety and efficacy of its investigational drugs ABSK061 combined with ABSK043, with or without chemotherapy, in patients with metastatic or unresectable solid tumors exhibiting FGFR2/3 alterations.
ABSK061: A Pioneering FGFR2/3 Inhibitor
ABSK061 is an oral, highly selective FGFR2/3 inhibitor and is the world’s first of its kind to enter clinical trials. As a second-generation FGFR inhibitor, ABSK061 is anticipated to offer a better safety profile and enhanced efficacy in clinical settings. The drug is also being explored for potential use in various non-tumoral indications, including chondrodysplasia.
ABSK043: An In-House PD-L1 Inhibitor
ABSK043 is an in-house developed oral programmed-death ligand 1 (PD-L1) inhibitor. It has demonstrated anti-tumor efficacy comparable to approved PD-L1 antibodies across multiple preclinical models. The combination of ABSK061 and ABSK043 holds promise for patients with FGFR2/3-altered tumors, potentially offering a novel treatment approach.-Fineline Info & Tech
Leave a Reply